tiprankstipranks
Proteome Sciences PLC (GB:PRM)
LSE:PRM
Want to see GB:PRM full AI Analyst Report?

Proteome Sciences (PRM) Price & Analysis

3 Followers

PRM Stock Chart & Stats

2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)

Bulls Say, Bears Say

Bulls Say
Specialized Proteomics ServicesProteome Sciences operates a highly specialized service niche—mass spectrometry proteomics for drug discovery and biological research. High technical barriers and domain expertise create durable competitive advantage, supporting repeat business from pharma/biotech customers and long-term demand for complex assays.
Contract Research Business ModelThe contract research model yields multi-project engagements and possible longer-term service agreements, which can produce recurring, project-based revenue. When client relationships deepen, this model supports predictable workflows and utilization, aiding revenue durability versus single-product cyclicality.
Improving Cash Generation TrendNear‑breakeven operating cash flow in 2025 signals improved cash discipline and operational control. Reduced cash burn increases runway and lowers immediate refinancing pressure, giving management time to pursue client wins and margin recovery before additional capital is required.
Bears Say
Revenue Decline & Negative Gross ProfitFalling revenue combined with negative gross profit indicates the business is not covering direct costs, a structural profitability issue. Without revenue stabilization or cost redesign, margin recovery is unlikely, reducing ability to fund R&D and retain technical staff needed for competitive service delivery.
Stressed Balance SheetHigh debt and deeply negative equity materially constrain financial flexibility. Refinancing risk and potential for dilution are structural constraints that limit investment in capacity or technology, heighten stakeholder pressure, and could force unfavorable financing or cost cuts that harm growth prospects.
Sustained Losses And Volatile Cash HistoryPersistent operating losses and historically volatile cash flows reduce predictability and raise recurring capital needs. This undermines long-term stability, makes multi-year planning harder, and increases dependence on external funding, which may be costly or dilutive given the weak balance sheet.

Proteome Sciences News

PRM FAQ

What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
    What is Proteome Sciences PLC’s market cap?
    Proteome Sciences PLC’s market cap is £5.26M.
      When is Proteome Sciences PLC’s upcoming earnings report date?
      Proteome Sciences PLC’s upcoming earnings report date is Jul 23, 2026 which is in 30 days.
        How were Proteome Sciences PLC’s earnings last quarter?
        Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
          Is Proteome Sciences PLC overvalued?
          According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Proteome Sciences PLC pay dividends?
            Proteome Sciences PLC does not currently pay dividends.
            What is Proteome Sciences PLC’s EPS estimate?
            Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Proteome Sciences PLC have?
            Proteome Sciences PLC has 350,724,900 shares outstanding.
              What happened to Proteome Sciences PLC’s price movement after its last earnings report?
              Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
                Which hedge fund is a major shareholder of Proteome Sciences PLC?
                Currently, no hedge funds are holding shares in GB:PRM
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Proteome Sciences PLC

                  Proteome Sciences plc, established in 1993 and based in Cobham, United Kingdom, specializes in delivering contract research services. The company's core expertise lies in the identification, validation, and practical application of protein biomarkers for clients across the United States, the United Kingdom, and the European Union. Its extensive portfolio includes a range of sophisticated proteomic solutions: SysQuant offers comprehensive insights into protein activity within regulatory and signaling pathways. For analyzing cells and tissues without the need for phosphopeptide enrichment, they provide TMT MS2. TMT MS3 is a critical method for biomarker discovery in complex samples, such as plasma, where precise quantification is paramount. The TMT Calibrator enables simultaneous analysis of diseased or treated tissue alongside peripheral fluids. Rapid validation of biomarker candidates is facilitated by TMT SRM, a targeted assay format. Additionally, the company performs SRM assays, a targeted mass spectrometry technique for routine biomarker measurement. Complementing these laboratory services, Proteome Sciences also offers a suite of bioinformatics tools. These include: Proteome Discoverer, utilized for peptide sequencing and TMT quantification. SQuaT, CalDIT, and DIANA, which normalize quantitative data and provide functional annotation for peptides and proteins. FeaST, a visualization tool for assessing data quality, building class identifier models, and generating biomarker candidate lists. FAT, designed to identify variations in biological processes and cellular components. The company's primary clientele comprises pharmaceutical and biotechnology firms, as well as academic research institutions.

                  Proteome Sciences (PRM) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  ANGLE plc
                  Genedrive
                  OptiBiotix Health
                  Verici Dx Plc
                  GENinCode UK Ltd.

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks